Sales of approximately $560 million, according to IMS Health data.. Actavis’ subsidiary documents ANDA for generic edition of NuvaRing Actavis plc today confirmed that its subsidiary, Warner Chilcott Organization LLC, has filed an Abbreviated New Medication Program with the U.S. Food and Drug Administration seeking acceptance to market Ethinyl Estradiol and Etonogestrel Vaginal Ring, 0.015 mg/24 hour and 0.12 mg/24 hour. Related StoriesAlnylam presents positive ongoing stage 2 open-label extension data for Patisiran and RevusiranAllergan settles patent litigation with Amneal related to NAMENDA XR prolonged release capsulesMylan sued in connection with ANDA filing for generic version of Zytiga Merck Sharp & Dohme B.V.After these doses were accomplished, 10 mg of isosorbide-5-mononitrate was initiated at bedtime, with a stepwise increase in the dose to no more than 20 mg twice a day or the maximum tolerated dose. In addition, within 7 to 14 days after the preliminary endoscopic treatment, the second, elective session of EBL was performed. EBL sessions were after that planned every 10 to 2 weeks until variceal eradication was attained . EBL sessions were performed by using multiband devices , and bands were applied starting at the gastroesophageal junction. Patients received proton-pump inhibitors until variceal eradication was accomplished.